Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial

Phase 1

Terminated

Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndromes

Interventions: Drug: Prexasertib
Drug: Mitoxantrone
Drug: Etoposide
Drug: Cytarabine

First Posted Date: 2018-11-08

Last Posted Date: 2019-06-12

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 2

Registration Number: NCT03735446

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma

Early Phase 1

Recruiting

Conditions: NK-Cell Leukemia
Peripheral T Cell Lymphoma
NK-Cell Lymphoma

Interventions: Drug: pralatraxate,
Drug: Methotrexate
Drug: Ifosfamide
Drug: cyclophosphamide
Drug: Dexamethasone
Drug: Doxorubicin
Drug: Etoposide
Drug: Prednisone
Drug: calaspargase pegol
Drug: Brentuximab Vedotin

First Posted Date: 2018-10-25

Last Posted Date: 2023-10-26

Lead Sponsor: New York Medical College

Target Recruit Count: 40

Registration Number: NCT03719105

Locations: 🇺🇸
Children's Hospital Orange County, Orange, California, United States
🇺🇸
Helen De Vos, Grand Rapids, Michigan, United States
🇺🇸
University of Alabama, Birmingham, Alabama, United States

and more 3 locations

Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)

Phase 3

Conditions: Extensive-stage Small Cell Lung Cancer

Interventions: Drug: SHR-1316
Drug: Carboplatin
Drug: Placebo
Drug: Etoposide

First Posted Date: 2018-10-18

Last Posted Date: 2022-04-18

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 462

Registration Number: NCT03711305

Locations: 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳
Jilin Cancer Hospital, Jilin, Changchun, China

A Study of Lobaplatin/Etoposide With or Without Anlotinib Maintenance Therapy in Patients With ES-SCLC

Phase 2

Conditions: Small Cell Lung Carcinoma

Interventions: Drug: Anlotinib Hydrochloride
Drug: Lobaplatin
Drug: Etoposide

First Posted Date: 2018-10-09

Last Posted Date: 2019-11-29

Lead Sponsor: The First Affiliated Hospital of Guangzhou Medical University

Target Recruit Count: 60

Registration Number: NCT03700359

Locations: 🇨🇳
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

Clinical Trial for Patients With a Stage IV Childhood Renal Tumor, Comparing Upfront Vincristine, Actinomycin-D and Doxorubicin (Standard Arm) With Upfront Vincristine, Carboplatin and Etoposide (Experimental Arm)

Phase 3

Not yet recruiting

Conditions: Childhood Renal Tumor

Interventions: Drug: treatment Vincristin
Drug: treatment Actinomycin-D
Drug: treatment Carboplatin
Drug: treatment Doxorubicin
Drug: Etoposide

First Posted Date: 2018-09-13

Last Posted Date: 2018-09-13

Lead Sponsor: Assistance Publique Hopitaux De Marseille

Target Recruit Count: 110

Registration Number: NCT03669783

Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

First Posted Date: 2018-08-22

Last Posted Date: 2023-11-29

Lead Sponsor: Martin Schrappe

Target Recruit Count: 5000

Registration Number: NCT03643276

Locations: 🇮🇹
AOUC Policlinico Bari, Bari, Italy
🇮🇹
A.O. Papa Giovanni XXIII, Bergamo, Italy
🇮🇹
S.O. Annunziata - A. O. Cosenza, Cosenza, Italy

and more 111 locations

Combination Chemotherapy With Pazopanib in Children and Adolescents With Relapsed/Refractory Solid Tumors

Phase 1

Not yet recruiting

Conditions: Refractory Pediatric Solid Tumor
Relapsed Pediatric Solid Tumor

Interventions: Drug: Pazopanib
Drug: Ifosfamide
Drug: Carboplatin
Drug: Etoposide

First Posted Date: 2018-08-14

Last Posted Date: 2018-09-19

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 46

Registration Number: NCT03628131

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients

Phase 2

Conditions: Experimental Tumor

Interventions: Drug: Chidamide
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Etoposide
Drug: Prednisone

First Posted Date: 2018-08-06

Last Posted Date: 2018-09-04

Lead Sponsor: Peking University

Target Recruit Count: 114

Registration Number: NCT03617432

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, China

A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML

Phase 2

Recruiting

Conditions: FLT3-mutated Acute Myeloid Leukemia

Interventions: Drug: Midostaurin
Drug: Fludarabine
Drug: Cytarabine
Drug: Daunorubicin or idarubicin
Drug: Mitoxantrone
Drug: Etoposide

First Posted Date: 2018-07-19

Last Posted Date: 2024-04-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 23

Registration Number: NCT03591510

Locations: 🇹🇷
Novartis Investigative Site, Istanbul, Turkey

Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas

Phase 1

Completed

Conditions: Peripheral T Cell Lymphoma

Interventions: Drug: Nivolumab
Drug: Etoposide
Drug: Prednisolone
Drug: Oncovin
Drug: Cyclophosphamide
Drug: Hydroxydaunorubicin

First Posted Date: 2018-07-16

Last Posted Date: 2024-10-29

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 18

Registration Number: NCT03586999

Locations: 🇺🇸
City of Hope Cancer Center, Duarte, California, United States
🇺🇸
University of Colorado Hospital, Aurora, Colorado, United States
🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy